AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
231.39
-0.67 (-0.29%)
Oct 21, 2025, 4:00 PM EDT - Market closed
AbbVie Revenue
AbbVie had revenue of $15.42B in the quarter ending June 30, 2025, with 6.65% growth. This brings the company's revenue in the last twelve months to $58.33B, up 6.05% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$58.33B
Revenue Growth
+6.05%
P/S Ratio
7.02
Revenue / Employee
$1,060,509
Employees
55,000
Market Cap
408.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
| Abbott Laboratories | 43.84B |
ABBV News
- 22 hours ago - The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients - PRNewsWire
- 1 day ago - AbbVie's Rinvoq shows superiority over Humira in head-to-head study - Reuters
- 1 day ago - RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor - PRNewsWire
- 4 days ago - AbbVie: "Strong Buy" On Rinvoq Expansions And Immunology Pipeline Addition - Seeking Alpha
- 4 days ago - AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin - PRNewsWire
- 8 days ago - U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease - PRNewsWire
- 8 days ago - AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors - PRNewsWire
- 12 days ago - SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer - PRNewsWire